REG - Physiomics PLC - Contract award

PhysiomicsAnnouncement

08/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220408:nRSH7002Ha&default-theme=true

RNS Number : 7002H  Physiomics PLC  08 April 2022

8 April 2022

 

Physiomics plc

("Physiomics") or ("the Company")

 

Contract award

 

Physiomics plc (AIM: PYC), the consultancy using mathematical models to
support the development of drug treatment regimens and personalised medicine
solutions, is pleased to announce that it has been awarded a contract by new
client, the Servier Group ("Servier"), an international pharmaceutical company
headquartered in France.  Cancer is one of Servier's priority therapy areas
and it has a particular focus on immunotherapies and monoclonal antibodies for
difficult to treat diseases with high unmet medical needs.

 

Physiomics will be providing specialist mathematical modelling services using
its Virtual Tumour software platform to model and simulate the effect of a
number of immuno-oncology combinations involving Servier drugs in development
in pre-clinical and clinical settings.  It is anticipated that the project
will be completed over the course of the next 7-8 months.

 

 

Physiomics CEO, Dr Jim Millen, commented: "We are delighted to have been
selected by Servier, one of France's leading pharmaceutical companies with a
truly global outlook as its partner for this modelling and simulation project
focused on pre-clinical and translational modelling of a novel immuno-oncology
agent in development.  We look forward to working with its talented
scientists."

 

 

Enquiries:

 

Physiomics
plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has
worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle
Therapeutics.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUPUBUCUPPGAM